This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zynerba Up on Second Patent for Cannabidiol Candidate in 2019
by Zacks Equity Research
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Insys Down on Bankruptcy News Amid Increasing Legal Expenses
by Zacks Equity Research
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
by Zacks Equity Research
Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
Insys Therapeutics (INSY) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insys Therapeutics (INSY) delivered earnings and revenue surprises of -323.08% and -48.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options
by Zacks Equity Research
Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.
Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Insys Therapeutics (INSY) closed the most recent trading day at $4.62, moving +1.99% from the previous trading session.
Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Insys Therapeutics (INSY) closed at $4.81 in the latest trading session, marking a +1.69% move from the prior day.
Insys Plunges on Auditor's Concern About Insufficient Funds
by Zacks Equity Research
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
by Zacks Equity Research
INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.
Insys Therapeutics (INSY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insys Therapeutics (INSY) delivered earnings and revenue surprises of -85.00% and -18.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings?
by Zacks Equity Research
Improvement in prescriptions growth rate of SUBSYS and SYNDROS to drive INSYS Therapeutics' (INSY) Q3 earnings.
Insys Therapeutics (INSY) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Insys Therapeutics (INSY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in INSYS Therapeutics (INSY) Stock?
by Zacks Equity Research
Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.
5 Best Stocks of the Top ETF of August
by Sweta Killa
Cannabis-related ETFMG Alternative Harvest ETF (MJ) is the best-performing ETF of August, gaining 22.5% and attracting $22 million in AUM.
Insys Therapeutics (INSY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insys Therapeutics (INSY) delivered earnings and revenue surprises of -120.00% and -7.67%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Zogenix's Epilepsy Candidate Successful in Phase III Study
by Zacks Equity Research
Zogenix's (ZGNX) shares rally after successful completion of confirmatory phase III study of ZX008 for treating Dravet syndrome.
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright
by Zacks Equity Research
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism.
INSYS Gets Negative FDA Recommendation for Pain Candidate
by Zacks Equity Research
INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.
4 Best Marijuana Stocks to Play the Green Rush
by Zacks Equity Research
Given the increasing bullish environment, the movement to legalize marijuana has definitely picked up steam. Below are four cannabis-linked stocks that are poised to benefit from legalization.
Insys' Cannabidiol Gets Fast Track Designation in the U.S.
by Zacks Equity Research
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
INSYS Therapeutics (INSY) Soars: Stock Adds 15.2% in Session
by Zacks Equity Research
INSYS Therapeutics (INSY) was a big mover last session, as the company saw its shares rise more than 15% on the day amid huge volumes.
Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.
STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up
by Zacks Equity Research
STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.